

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A therapeutic agent for nerve damage comprising, as an active ingredient, a low-molecular-weight saccharide composed of at least comprising glucuronic acid and/or N-acetylglucosamine or a pharmaceutically acceptable salt thereof.
2. (Currently Amended) The therapeutic agent according to claim 1, wherein the low-molecular-weight saccharide composed at least glucuronic acid and/or N-acetylglucosamine is a low-molecular-weight hyaluronic acid.
3. (Original) The therapeutic agent according to claim 2, wherein the low-molecular-weight hyaluronic acid is hyaluronic acid disaccharide to hyaluronic acid 2,500-saccharide.
4. (Original) The therapeutic agent according to claim 3, wherein the low-molecular-weight hyaluronic acid is hyaluronic acid disaccharide to hyaluronic acid 50-saccharide.
5. (Original) The therapeutic agent according to claim 4, wherein the low-molecular-weight hyaluronic acid is hyaluronic acid tetrasaccharide.
6. (Currently Amended) The therapeutic agent according to ~~any one of claims 1 to 5~~ claim 1, wherein nerve damage is caused by spinal cord injury or nerve trauma.
7. (Currently Amended) A method of treating nerve damage, comprising administering an effective amount of a low-molecular-weight saccharide composed of comprising at least glucuronic acid and/or N-acetylglucosamine or a pharmaceutically acceptable salt thereof to an animal suffering from nerve damage.
8. (Currently Amended) ~~A method of manufacturing a therapeutic agent for nerve damage~~ ~~Use of which comprises dissolving a low-molecular-weight saccharide composed of at least comprising glucuronic acid and/or N-acetylglucosamine or a pharmaceutically acceptable salt thereof in a solvent commonly used for drugs~~ manufacturing a therapeutic agent for nerve damage.